Skip to content

Research on the inheritance of academic thought of spleen and stomach diseases of national famous Chinese medicine and the clinical development of thirteen flavors and middle pills

Research on the inheritance of academic thought of spleen and stomach diseases of national famous Chinese medicine and the clinical development of thirteen flavors and middle pills

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079000
Enrollment
Unknown
Registered
2023-12-22
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

Experimental group:Shisanwei Hezhong Pill and Mosapride Citrate Simulated Capsule
Control group 1:Shisanwei Hezhong Pill simulation agent and Mosapride Citrate Capsules
Control group 2 :Shisanwei Hezhong Pill and Mosapride Citrate Capsules

Sponsors

The second affiliated Hospital of Anhui University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: ( 1 ) According to the diagnostic criteria of Rome IV functional dyspepsia and liver-stomach disharmony type of traditional Chinese medicine ; ( 2 ) 18 years old = age = 65 years old, regardless of gender ; ( 3 ) Subjects signed informed consent voluntarily with their informed consent ; ( 4 ) Have a certain reading ability. ( Note : Patients who meet the above four criteria at the same time can be included in this study. )

Exclusion criteria

Exclusion criteria: ( 1 ) Complicated with gastric and twelve intestinal ulcers, mucosal erosion and bleeding under gastroscope, pathological examination showed gastric mucosal atrophy, intestinal metaplasia or dysplasia, or systemic diseases affecting gastrointestinal motility ( such as diabetes, chronic renal insufficiency, connective tissue disease, mental and neurological diseases, etc. ) ; ( 2 ) Have taken or are taking drugs or antibiotics that affect gastrointestinal motility or gastric acid secretion within 2 weeks ; ( 3 ) Patients with severe brain, heart, liver, kidney, lung, hematopoietic system, endocrine system and autoimmune diseases ; ( 4 ) malignant tumors or other serious consumptive diseases, infectious diseases, hemorrhagic diseases, etc. ; ( 5 ) those with severe mental and psychological disorders ( HAMA = 21 points with obvious anxiety ) ; ( 6 ) Lactating women and women who are preparing for or have become pregnant. ( 7 ) Suspected or had a history of alcohol and drug abuse ; or according to the judgment of the researcher, other situations that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in the working environment, are likely to cause loss of follow-up. ( Note : Anyone who meets any of the above items is excluded from this topic. )

Design outcomes

Primary

MeasureTime frame
TCM symptom score of functional dyspepsia;Gastric emptying rate;serum calcitonin gene-related peptide;gastrin;Motilin;Somatostatin ( SST );Substance P;5-Hydroxytryptamine;Nipin dyspepsia symptom index;Nipin dyspepsia quality of life index;Hamilton anxiety scale;Efficacy evaluation of functional dyspepsia: effective / ineffective;

Countries

China

Contacts

Public ContactHaoran Chu

The second affiliated Hospital of Anhui University of traditional Chinese Medicine

chuhaoran62@163.com+86 138 5510 7535

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026